ArticleCJC open2026
Beta-Blockers for Vasovagal Syncope in Aging Subjects: A Randomized Controlled Trial and Individual Patient Data Meta-Analysis of Clinical Trials.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02123056 (Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies provided conflicting evidence of benefit of beta-blockers (BBs) in preventing vasovagal syncope (VVS), with possible benefit in older adults, leading to North American guidelines accepting BBs as a reasonable but weak option in patients aged ≥ 42 years with VVS (class IIb). In the Methods: Patients aged ≥ 40 years with ≥ 1 syncopal spell in the prior year and ≥ -2 points for the Calgary Syncope Symptom Score were randomized to receive either metoprolol or matching placebo for 12 months. Patient-level meta-analysis of patients with age ≥ 40 years was done for randomized controlled trials (RCTs) studying the effect of BBs in VVS. Results: A total of 51 patients (age 64 ± 11 years, 59% female) were included in POST 5 (26 metoprolol, 25 placebo). Treatment arms were balanced in demographic and clinical characteristics. Eight patients (31%) in the metoprolol arm and 10 (40%) in the placebo arm experienced syncope during a median follow-up period of 12 months ( Conclusion: BBs showed no effect on reducing syncope recurrence in older patients with VVS. These results may inform practice guidelines by removing their recommendations for using BBs in this specific context. Clinical Trial Registration: NCT02123056.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.